This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (72)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephen C. Marker, MD; Richard J. Howard, MD, PhD; Karl E. Groth; Angeline R. Mastri, MD; Richard L. Simmons, MD; Henry H. Balfour, Jr, MD

Arch Intern Med. 1980;140(11):1441-1444.

Abstract
• Vidarabine was evaluated in renal transplant patients as a potential therapeutic agent in cytomegalovirus (CMV) infection. Four patients received vidarabine on an open protocol, then ten additional patients were enrolled in a double-blind protocol. Among the nine patients who received vidarabine, no notable clinical improvement occurred in either the vidarabine- or placebo-treated groups. Thus, vidarabine showed no therapeutic effect in the treatment of CMV infections at the dosages used. Four patients showed dramatic CNS deterioration within several days of the onset of vidarabine therapy. Tremors and myoclonus were common, and one patient had unusual brain pathologic changes with widespread neuronal chromatolysis. The pathologic findings in the brain in the other three patients were complex and included intracerebral hemorrhage, Fabry's disease, coccidioidomycosis meningitis, and cerebral vascular occlusion. Thus, there was no conclusive proof that vidarabine contributed to the sudden neurologic deterioration of these patients.

(Arch Intern Med 140:1441-1444, 1980)

Author Affiliations
From the Section of Virology, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology (Drs Marker, Mastri, and Balfour and Mr Groth), and Department of Surgery (Drs Howard and Simmons), University of Minnesota, Minneapolis.

Footnotes
Accepted for publication Dec 10, 1979.

Reprint requests to Box 198, Mayo Memorial Building, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455 (Dr Marker).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antiviral Drugs in Pediatrics
Balfour and Englund
Arch Pediatr Adolesc Med 1989;143:1307-1316.
ABSTRACT  

Ocular Toxicity of Intravitreal Vidarabine Solubilized in Dimethyl Sulfoxide
Yoshizumi et al.
Arch Ophthalmol 1986;104:426-430.
ABSTRACT  

Myelopathy After Herpes Zoster
Muder et al.
Arch Neurol 1983;40:445-446.
ABSTRACT  

Neurologic Symptoms Associated with Parenteral Acyclovir Treatment After Marrow Transplantation
WADE and MEYERS
ANN INTERN MED 1983;98:921-925.
ABSTRACT  

Diagnosis of Herpes Simplex Encephalitis-Reply
Whitley and Alford
JAMA 1982;248:547-548.
ABSTRACT  

Fatal Vidarabine Toxicity in a Patient With Normal Renal Function
Etta et al.
JAMA 1981;246:1703-1705.
ABSTRACT